David D. Berg

David D. Berg

Auto-generated profile, based on publicly available information

David D. Berg

Harvard Medical School

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in JAMA Cardiology
Verified
Journal Article
Open access
PDF file
DBDavid D. Berg
David D. Berg
PJPardeep S. Jhund
Pardeep S. Jhund
KDKieran F. Docherty
Kieran F. Docherty
SMSabina A. Murphy
Sabina A. Murphy
SVSubodh Verma
Subodh Verma
MSMarc S. Sabatine
Marc S. Sabatine
In the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial, treatment with the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin, added to other guideline-directed medical therapy, reduced the risk of worsening heart failure (HF) events and cardiovascular death in patients with HF with reduced ejection fraction (HFrEF) (hazard ratio [HR], 0.74; 95% CI, 0.65-0.85; P < .001).1 With many different therapeutic options available for patients with HFrEF, clinical inertia often underlies deferred initiation of additional beneficial therapy, which ultimately leads to preventable adverse HF events.2 To frame these potential lost opportunities with respect to dapagliflozin, we examined the timing of onset of clinical benefit with dapagliflozin in the DAPA-HF trial.

19 May 2021 in Current Opinion in Critical Care
Verified
Journal Article
Closed access
DBDavid D. Berg
David D. Berg
EBErin A. Bohula
Erin A. Bohula
DMDavid A. Morrow
David A. Morrow
Purpose of review: Cardiogenic shock is a complex clinical syndrome of end-organ hypoperfusion due to impaired cardiac performance. Although cardiogenic shock has traditionally been viewed as a monolithic disorder predominantly caused by severe left ventricular dysfunction complicating acute myocardial infarction (AMI), there is increasing recognition of the diverse causes of cardiogenic shock and wide spectrum of clinical severity. The purpose of this review is to describe the contemporary epidemiology of cardiogenic shock, including trends in clinical outcomes and recent efforts to refine risk assessment. Recent findings: The incidence of cardiogenic shock among patients with AMI has remained remarkably stable at 3–10%; however, the proportion of cardiogenic shock cases related to AMI has decreased over time to ∼30%, while the proportion of cardiogenic shock cases due to acute decompensated heart failure has steadily increased. Estimated in-hospital mortality from cardiogenic shock in contemporary registries is approximately 30–40%, suggesting modest improvement in cardiogenic shock outcomes over the last decade. There is a wide spectrum of clinical severity among patients presenting with cardiogenic shock, which is described by the Society for Cardiovascular Angiography and Interventions clinical staging criteria. Summary: Improved clinical characterization and risk assessment of patients with cardiogenic shock may facilitate more effective clinical investigations of this morbid clinical syndrome.

1 October 2021 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
ABAnkeet S. Bhatt
Ankeet S. Bhatt
DBDavid D. Berg
David D. Berg
EBErin A. Bohula
Erin A. Bohula
CACarlos L. Alviar
Carlos L. Alviar
VBVivian M. Baird-Zars
Vivian M. Baird-Zars
DMDavid A. Morrow
David A. Morrow

29 August 2022 in Circulation
Verified
Journal Article
Closed access
PDF file
EBErin A. Bohula
Erin A. Bohula
DBDavid D. Berg
David D. Berg
MLMathew S. Lopes
Mathew S. Lopes
JCJean Connors
Jean Connors
IBIljal Babar
Iljal Babar
DMDavid A. Morrow
David A. Morrow
Background: The efficacy and safety of prophylactic full-dose anticoagulation and antiplatelet therapy in critically ill COVID-19 patients remain uncertain. Methods: COVID-PACT (Prevention of Arteriovenous Thrombotic Events in Critically-ill COVID-19 Patients Trial) was a multicenter, 2×2 factorial, open-label, randomized-controlled trial with blinded end point adjudication in intensive care unit–level patients with COVID-19. Patients were randomly assigned to a strategy of full-dose anticoagulation or standard-dose prophylactic anticoagulation. Absent an indication for antiplatelet therapy, patients were additionally randomly assigned to either clopidogrel or no antiplatelet therapy. The primary efficacy outcome was the hierarchical composite of death attributable to venous or arterial thrombosis, pulmonary embolism, clinically evident deep venous thrombosis, type 1 myocardial infarction, ischemic stroke, systemic embolic event or acute limb ischemia, or clinically silent deep venous thrombosis, through hospital discharge or 28 days. The primary efficacy analyses included an unmatched win ratio and time-to-first event analysis while patients were on treatment. The primary safety outcome was fatal or life-threatening bleeding. The secondary safety outcome was moderate to severe bleeding. Recruitment was stopped early in March 2022 (≈50% planned recruitment) because of waning intensive care unit–level COVID-19 rates. Results: At 34 centers in the United States, 390 patients were randomly assigned between anticoagulation strategies and 292 between antiplatelet strategies (382 and 290 in the on-treatment analyses). At randomization, 99% of patients required advanced respiratory therapy, including 15% requiring invasive mechanical ventilation; 40% required invasive ventilation during hospitalization. Comparing anticoagulation strategies, a greater proportion of wins occurred with full-dose anticoagulation (12.3%) versus standard-dose prophylactic anticoagulation (6.4%; win ratio, 1.95 [95% CI, 1.08–3.55]; P =0.028). Results were consistent in time-to-event analysis for the primary efficacy end point (full-dose versus standard-dose incidence 19/191 [9.9%] versus 29/191 [15.2%]; hazard ratio, 0.56 [95% CI, 0.32–0.99]; P =0.046). The primary safety end point occurred in 4 (2.1%) on full dose and in 1 (0.5%) on standard dose ( P =0.19); the secondary safety end point occurred in 15 (7.9%) versus 1 (0.5%; P =0.002). There was no difference in all-cause mortality (hazard ratio, 0.91 [95% CI, 0.56–1.48]; P =0.70). There were no differences in the primary efficacy or safety end points with clopidogrel versus no antiplatelet therapy. Conclusions: In critically ill patients with COVID-19, full-dose anticoagulation, but not clopidogrel, reduced thrombotic complications with an increase in bleeding, driven primarily by transfusions in hemodynamically stable patients, and no apparent excess in mortality. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04409834.

5 December 2024 in JACC: Advances
Verified
Journal Article
Open access
JJJacob C. Jentzer
Jacob C. Jentzer
DBDavid D. Berg
David D. Berg
MCMeshe D. Chonde
Meshe D. Chonde
GDGarima Dahiya
Garima Dahiya
AEAndrea Elliott
Andrea Elliott
Saraschandra VallabhajosyulaSaraschandra Vallabhajosyula
Saraschandra Vallabhajosyula
This state-of-the-art review describes the potential etiologies, pathophysiology, and management of mixed shock in the context of a proposed novel classification system. Cardiogenic-vasodilatory shock occurs when cardiogenic shock is complicated by inappropriate vasodilation, impairing compensatory mechanisms, and contributing to worsening shock. Vasodilatory-cardiogenic shock occurs when vasodilatory shock is complicated by myocardial dysfunction, resulting in low cardiac output. Primary mixed shock occurs when a systemic insult triggers both myocardial dysfunction and vasoplegia. Regardless of the etiology of mixed shock, the hemodynamic profile can be similar, and outcomes tend to be poor. Identification and treatment of both the initial and complicating disease processes is essential along with invasive hemodynamic monitoring given the evolving nature of mixed shock states. Hemodynamic support typically involves a combination of inotropes and vasopressors, with few data available to guide the use of mechanical circulatory support. Consensus definitions and novel treatment strategies are needed for this dangerous condition.

1 July 2020 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
AMAravind A. Menon
Aravind A. Menon
DBDavid D. Berg
David D. Berg
EBElliot J. Brea
Elliot J. Brea
ADAaron Deutsch
Aaron Deutsch
KKKhameer K. Kidia
Khameer K. Kidia
LFLaura E. Fredenburgh
Laura E. Fredenburgh